Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20565707 | 0.80 | RAB9A (0.41) | MAPTRAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL30579310 | 0.77 | SMPD3 (0.35) | MAPTRAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL20565659 | 0.77 | RAB9A (0.39) | MAPTRAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL13304717 | 0.77 | RAB9A (0.42) | MAPTRAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL1244741 | 0.77 | AXL (0.43) | MAPTRAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL23104339 | 0.77 | KDM4E (0.56) | MAPTRAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL20558034 | 0.77 | GPR119 (0.36) | MAPTRAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL23728449 | 0.73 | KDM4E (0.37) | KDM4EHTTCLK4 | |
| SCHEMBL23728419 | 0.73 | GPR119 (0.36) | KDM4EALDH1A1HTTHPGDCLK4 | |
| SCHEMBL3321504 | 0.73 | KDM4E (0.34) | KDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3169671-B1 | 1-(5-(TERT.-BUTYL)ISOXAZOL-3-YL)-3-(4-((PHENYL)ETHYNYL)PHENYL)UREA DERIVATIVES AND RELATED COMPOUNDS AS FLT3 INHIBITORS FOR TREATING CANCER | SUNSHINE LAKE PHARMA CO LTD (CN) | 2019-08-21 | — | — | EP | disclosed |
| US-10065934-B2 | Substituted urea derivatives and pharmaceutical uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-09-04 | — | — | US | disclosed |
| US-20170114032-A1 | SUBSTITUTED UREA DERIVATIVES AND PHARMACEUTICAL USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-04-27 | — | — | US | disclosed |
| US-20170114032-A1 | SUBSTITUTED UREA DERIVATIVES AND PHARMACEUTICAL USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-04-27 | — | — | US | disclosed |
| US-20170114032-A1 | SUBSTITUTED UREA DERIVATIVES AND PHARMACEUTICAL USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-04-27 | — | — | US | disclosed |
| WO-2016008433-A1 | SUBSTITUTED UREA DERIVATIVES AND PHARMACEUTICAL USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114032-A1 | SUBSTITUTED UREA DERIVATIVES AND PHARMACEUTICAL USES THEREOF | ULK2, ULK3, ULK1 | MAPT 857/4885RAB9A 1735/4885NPC1 1201/4885 |
| US-10065934-B2 | Substituted urea derivatives and pharmaceutical uses thereof | ULK2, ULK3, ULK1 | MAPT 857/4885RAB9A 1735/4885NPC1 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.